In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CStone closes $260mm Series B round; largest in Chinese biopharm history

Executive Summary

Immuno-oncology firm CStone Pharmaceuticals Co. Ltd. raised $260mm through its Series B round, the largest funding of its kind in Chinese biopharma history. GIC Private Ltd. led and was joined by new investors Sequoia China, Yunfeng Capital, 6 Dimensions Capital, CITIC PE, Taikang Insurance Group, Arch Venture Partners, Hillhouse Capital, King Star Capital, 3W Partners, AVICT, and Terra Mafnum Capital Partners, as well as returning backers Oriza Seed Venture Capital, Boyu Capital, and WuXi Healthcare Ventures. Funds will support continued development of lead candidate CS1001, an anti-PD-L1 mAb in Phase I/II for advanced cancers.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register